MedCity News
“While FDA approval has long been a singular prize, companies should also mine their assets for the strongest commercial opportunities. …the ability to take a drug to market is an important milestone, but it is not the entire picture. To truly move the needle, both clinically and commercially, biopharma companies must fine-tune their teams, approaches and incentives to produce unique and innovative products.”Read more from Leslie Orne’s new op-ed in MedCity News entitled, “Balancing Risk and Opportunities to Choose Winning…
Read Now
Black Doctor
Trinity Life Sciences’ recent white paper on diversity in clinical trials was mentioned in an article published on Black Doctor.
Read Now…
Read Now
Fierce Biotech
Fierce Biotech mentioned Trinity Life Sciences’ recent white paper, Diversity in Clinical Trials: Life Sciences Initiatives and Challenges in Light of the FDA’s Latest Guidance, in their coverage of the updated FDA guidance.
Read Now…
Read Now
Fierce Biotech
Trinity Life Sciences’ recent white paper, Diversity in Clinical Trials: Life Sciences Initiatives and Challenges in Light of the FDA’s Latest Guidance, was featured in an article from Fierce Biotech highlighting how mistrust in the healthcare system is holding back trial diversity.
Read Now…
Read Now
HIT Consultant
Trinity’s Lisa Bailey, Ph.D., Managing Director & Head of DEI Strategy, was featured in an article by HIT Consultant. Learn more about the importance of diverse clinical trial populations in achieving equitable healthcare.
Read Now…
Read Now
AI Time Journal
Aparna Deshpande, PhD, Trinity’s Head of Insights & Analytics, was featured in an interview with AI Time Journal. Read the article to learn more about driving pharmaceutical innovation through Insights and Analytics.
Read Now…
Read Now
MM+M
Trinity’s Lisa Bailey, Ph.D., Managing Director & Head of DEI Strategy, was featured in an article by MM+M. Learn about Trinity’s study on the most pressing challenges facing efforts to include more diverse patient populations in clinical trial research and what drugmakers can do at the corporate level to make a difference.
Read Now…
Read Now
PharmaVoice
“When you look at the list of 50-plus FDA approvals [in 2023], we know from pattern recognition that there’s going to be winners and losers, and some who have to work harder for it — we’ve seen increasing difficulty of achieving success,” said Leslie Orne. Read more from Leslie Orne, Trinity Life Sciences’ President and CEO, in PharmaVoice‘s latest article on ‘Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills.’
Read Now…
Read Now
Endpoint News
The Annual Digital Marketing Competency Report was featured in Endpoint News.
Read Now…
Read Now
Pharmaceutical Executive
Leslie Orne speaks with Pharmaceutical Executive about current trends in the life sciences industry and the ways that companies can react.
Read Now…
Read Now
